LifeLink® Tissue Bank and Britecyte® Join Forces to Pioneer Advancements in Adipose Tissue Technolog

LifeLink® Tissue Bank and Britecyte® Join Forces to Pioneer Advancements in Adipose Tissue Technology

LifeLink Tissue Bank, a globally recognized non-profit leader in providing lifesaving and life-enhancing tissue allografts, made possible by the generosity of tissue donors and their families, announces a strategic relationship with Britecyte®, Inc., a biotechnology company at the forefront of regenerative medicine therapies. This collaboration launches an innovative platform technology focusing on the recovery, processing, and clinical application of adipose tissue. 

Samson Tom, President, CEO, and Co-Founder of Britecyte, expressed enthusiasm about the collaboration, stating, "We are proud to align ourselves with LifeLink Tissue Bank in this groundbreaking venture. The partnership leverages the strengths of both organizations to advance the field of regenerative medicine, particularly in the clinical use of adipose tissue." 

The joint development effort has yielded a state-of-the-art platform that provides a novel alternative to autologous fat grafting for the repair of soft tissue defects. Notably, this technology addresses challenges associated with fat pad atrophy, which currently has limited treatment options. Fat pad atrophy is a condition that refers to the thinning or loss of adipose tissue on the plantar surface of the foot. As a result, excessive pressure in the affected areas could lead to significant pain and disability, including the development of recurrent foot ulcers. 

Michael Consilvio, Executive Director/General Manager of LifeLink Tissue Bank, remarked, "Our collaboration with Britecyte has not only expanded the scope of our tissue offerings but has also allowed us to recover and process a new tissue source, which is important for our mission. This innovative platform has the potential to transform the landscape of adipose tissue applications in regenerative medicine." 

Highlighting this partnership was the introduction of Liposana™, Britecyte’s cutting-edge regenerative medicine solution, at the American College of Foot and Ankle Surgeons (ACFAS) meeting in Tampa, Florida, from February 1st-4th, 2024. Attendees discovered Liposana’s capabilities and learned about the latest advancements in adipose tissue technology.  

For more information on Britecyte and its expanding portfolio of regenerative medicine therapies, please visit the Britecyte official website.